Evidence map›Paper›PMID 22592864›Full record

Trial reportThe journal of headache and pain2012

Frovatriptan versus almotriptan for acute treatment of menstrual migraine: analysis of a double-blind, randomized, cross-over, multicenter, Italian, comparative study.

Marco Bartolini, Maria Adelaide Giamberardino, Carlo Lisotto, Paolo Martelletti, Davide Moscato, Biagio Panascia, Lidia Savi, Luigi Alberto Pini, Grazia Sances, Patrizia Santoro and 5 more

Open access · goldAbstract readComparative StudyMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The journal of headache and pain, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 3 pooled it
2.5field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 3 syntheses or guidelines pooled it, 41 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Efficacy of frovatriptan versus other triptans in the acute treatment of menstrual migraine: pooled analysis of three double-blind, randomized, crossover, multicenter studies.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2012
    Trial
  5. Review
  6. Review
  7. Review
  8. Review
  9. A review of frovatriptan for the treatment of menstrual migraine.International journal of women's health · 2014
    Review
  10. Article
  11. Treatment of perimenstrual migraine with triptans: an update.Current pain and headache reports · 2012
    Review
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 14 institutions in 2 countries.

Marco BartoliniClinica Neurologica, Ospedali Riuniti, Università Politecnica delle Marche, Ancona, Italy.
Maria Adelaide Giamberardino
Carlo Lisotto
Paolo Martelletti
Davide Moscato
Biagio Panascia
Lidia Savi
Luigi Alberto Pini
Grazia Sances
Patrizia Santoro
Giorgio Zanchin
Stefano Omboni
Michel D Ferrari
Brigida Fierro
Filippo Brighina
University of Palermo · ITAzienda Ospedaliera San Gerardo · ITAzienda Ospedaliero-Universitaria Policlinico - Vittorio Emanuele · ITCarlo Forlanini Hospital · ITIstituti di Ricovero e Cura a Carattere Scientifico · ITItalian Institute of Telemedicine · ITLeiden University Medical Center · NLMarche Polytechnic University · ITOspedale Vito Fazzi · ITSapienza University of Rome · ITUniversity of Chieti-Pescara · ITUniversity of Modena and Reggio Emilia · ITUniversity of Padua · ITUniversity of Turin · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The objective of the study was to compare the efficacy and safety of frovatriptan and almotriptan in women with menstrually related migraine (IHS Classification of Headache disorders) enrolled in a multicenter, randomized, double-blind, cross-over study. Patients received frovatriptan 2.5 mg or almotriptan 12.5 mg in a randomized sequence: after treating 3 episodes of migraine in no more than 3 months with the first treatment, the patient was switched to the other treatment. 67 of the 96 female patients of the intention-to-treat population of the main study had regular menstrual cycles and were thus included in this subgroup analysis. 77 migraine attacks classified as related to menses were treated with frovatriptan and 78 with almotriptan. Rate of pain relief at 2 and 4 h was 36 and 53 % for frovatriptan and 41 and 50 % for almotriptan (p = NS between treatments). Rate of pain free at 2 and 4 h was 19 and 47 % with frovatriptan and 29 and 54 % for almotriptan (p = NS). At 24 h, 62 % of frovatriptan-treated and 67 % of almotriptan-treated patients had pain relief, while 60 versus 67 % were pain free (p = NS). Recurrence at 24 h was significantly (p < 0.05) lower with frovatriptan (8 vs. 21 % almotriptan). This was the case also at 48 h (9 vs. 24 %, p < 0.05). Frovatriptan was as effective as almotriptan in the immediate treatment of menstrually related migraine attacks. However, it showed a more favorable sustained effect, as shown by a lower rate of migraine recurrence.

Indexed as

AdultCarbazolesCross-Over StudiesDisability EvaluationDouble-Blind MethodFemaleHumansItalyMenstruation DisturbancesMiddle AgedMigraine DisordersProportional Hazards ModelsSerotonin Receptor AgonistsSeverity of Illness IndexTime FactorsTreatment OutcomealmotriptanCarbazolesfrovatriptanSerotonin Receptor AgonistsTryptamines

Identifiers

PMID22592864
PMCPMC3381066
OpenAlexW2053241483

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.